Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Protective efficacy induced by recombinant Clostridium difficile toxin fragments.

Leuzzi R, Spencer J, Buckley A, Brettoni C, Martinelli M, Tulli L, Marchi S, Luzzi E, Irvine J, Candlish D, Veggi D, Pansegrau W, Fiaschi L, Savino S, Swennen E, Cakici O, Oviedo-Orta E, Giraldi M, Baudner B, D'Urzo N, Maione D, Soriani M, Rappuoli R, Pizza M, Douce GR, Scarselli M.

Infect Immun. 2013 Aug;81(8):2851-60. doi: 10.1128/IAI.01341-12. Epub 2013 May 28.

2.

Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.

Karczewski J, Zorman J, Wang S, Miezeiewski M, Xie J, Soring K, Petrescu I, Rogers I, Thiriot DS, Cook JC, Chamberlin M, Xoconostle RF, Nahas DD, Joyce JG, Bodmer JL, Heinrichs JH, Secore S.

Vaccine. 2014 May 19;32(24):2812-8. doi: 10.1016/j.vaccine.2014.02.026. Epub 2014 Mar 21.

PMID:
24662701
3.

Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.

Qiu H, Cassan R, Johnstone D, Han X, Joyee AG, McQuoid M, Masi A, Merluza J, Hrehorak B, Reid R, Kennedy K, Tighe B, Rak C, Leonhardt M, Dupas B, Saward L, Berry JD, Nykiforuk CL.

PLoS One. 2016 Jun 23;11(6):e0157970. doi: 10.1371/journal.pone.0157970. eCollection 2016.

4.

Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.

Anosova NG, Brown AM, Li L, Liu N, Cole LE, Zhang J, Mehta H, Kleanthous H.

J Med Microbiol. 2013 Sep;62(Pt 9):1394-404. doi: 10.1099/jmm.0.056796-0. Epub 2013 Mar 21.

PMID:
23518659
5.

Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.

Maynard-Smith M, Ahern H, McGlashan J, Nugent P, Ling R, Denton H, Coxon R, Landon J, Roberts A, Shone C.

Vaccine. 2014 Feb 3;32(6):700-5. doi: 10.1016/j.vaccine.2013.11.099. Epub 2013 Dec 14.

6.

A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters.

Wang YK, Yan YX, Kim HB, Ju X, Zhao S, Zhang K, Tzipori S, Sun X.

Hum Vaccin Immunother. 2015;11(9):2215-22. doi: 10.1080/21645515.2015.1052352. Epub 2015 Jun 2.

7.

Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity.

Romano MR, Leuzzi R, Cappelletti E, Tontini M, Nilo A, Proietti D, Berti F, Costantino P, Adamo R, Scarselli M.

Toxins (Basel). 2014 Apr 22;6(4):1385-96. doi: 10.3390/toxins6041385.

8.

The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model.

Guo S, Yan W, McDonough SP, Lin N, Wu KJ, He H, Xiang H, Yang M, Moreira MA, Chang YF.

Vaccine. 2015 Mar 24;33(13):1586-95. doi: 10.1016/j.vaccine.2015.02.006. Epub 2015 Feb 16.

PMID:
25698490
9.

An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.

Baliban SM, Michael A, Shammassian B, Mudakha S, Khan AS, Cocklin S, Zentner I, Latimer BP, Bouillaut L, Hunter M, Marx P, Sardesai NY, Welles SL, Jacobson JM, Weiner DB, Kutzler MA.

Infect Immun. 2014 Oct;82(10):4080-91. doi: 10.1128/IAI.01950-14. Epub 2014 Jul 14.

10.

A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.

Wang H, Sun X, Zhang Y, Li S, Chen K, Shi L, Nie W, Kumar R, Tzipori S, Wang J, Savidge T, Feng H.

Infect Immun. 2012 Aug;80(8):2678-88. doi: 10.1128/IAI.00215-12. Epub 2012 May 21.

12.

A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.

Tian JH, Fuhrmann SR, Kluepfel-Stahl S, Carman RJ, Ellingsworth L, Flyer DC.

Vaccine. 2012 Jun 13;30(28):4249-58. doi: 10.1016/j.vaccine.2012.04.045. Epub 2012 Apr 23.

PMID:
22537987
13.

Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection.

Yang Z, Shi L, Yu H, Zhang Y, Chen K, Saint Fleur A, Bai G, Feng H.

Pathog Dis. 2016 Oct;74(7). pii: ftw078. doi: 10.1093/femspd/ftw078. Epub 2016 Aug 7.

PMID:
27502696
14.

Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.

Carter GP, Chakravorty A, Pham Nguyen TA, Mileto S, Schreiber F, Li L, Howarth P, Clare S, Cunningham B, Sambol SP, Cheknis A, Figueroa I, Johnson S, Gerding D, Rood JI, Dougan G, Lawley TD, Lyras D.

MBio. 2015 Jun 2;6(3):e00551. doi: 10.1128/mBio.00551-15.

15.

Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.

Zhang Z, Chen X, Hernandez LD, Lipari P, Flattery A, Chen SC, Kramer S, Polishook JD, Racine F, Cape H, Kelly CP, Therien AG.

Infect Immun. 2015 Jan;83(1):405-16. doi: 10.1128/IAI.02550-14. Epub 2014 Nov 10. Erratum in: Infect Immun. 2015 Dec;83(12):4899.

16.

A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile.

Donald RG, Flint M, Kalyan N, Johnson E, Witko SE, Kotash C, Zhao P, Megati S, Yurgelonis I, Lee PK, Matsuka YV, Severina E, Deatly A, Sidhu M, Jansen KU, Minton NP, Anderson AS.

Microbiology. 2013 Jul;159(Pt 7):1254-66. doi: 10.1099/mic.0.066712-0. Epub 2013 Apr 29.

17.

Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.

Permpoonpattana P, Hong HA, Phetcharaburanin J, Huang JM, Cook J, Fairweather NF, Cutting SM.

Infect Immun. 2011 Jun;79(6):2295-302. doi: 10.1128/IAI.00130-11. Epub 2011 Apr 11.

18.

The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.

Yang XQ, Zhao YG, Chen XQ, Jiang B, Sun DY.

BMC Gastroenterol. 2013 Jul 17;13:117. doi: 10.1186/1471-230X-13-117.

19.

Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.

Steele J, Mukherjee J, Parry N, Tzipori S.

J Infect Dis. 2013 Jan 15;207(2):323-30. doi: 10.1093/infdis/jis669. Epub 2012 Nov 2.

20.

Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.

Andersen KK, Strokappe NM, Hultberg A, Truusalu K, Smidt I, Mikelsaar RH, Mikelsaar M, Verrips T, Hammarström L, Marcotte H.

Infect Immun. 2015 Nov 16;84(2):395-406. doi: 10.1128/IAI.00870-15.

Supplemental Content

Support Center